Table 3.
Multivariable Cox regression analyses.
| Variables | Univariable P value |
Mutivariable Cox regression | |
|---|---|---|---|
| P value | HR (95 CI) | ||
| BSV | - | - | Reference |
| ETV vs. BSV | 0.029 | 0.026 | 2.938 (1.139, 7.575) |
| TAF vs. BSV | 0.090 | 0.040 | 2.810 (1.048, 7.536) |
| TDF vs. BSV | 0.031 | 0.009 | 3.553 (1.366, 9.242) |
| Age (year) | < 0.001 | 0.013 | 1.030 (1.006, 1.054) |
| Hypertension | < 0.001 | 0.018 | 1.722 (1.098, 2.699) |
| Cirrhosis | < 0.001 | < 0.001 | 5.876 (3.087, 11.18) |
| Significant alcohol intake | 0.002 | 0.084 | 1.699 (0.931, 3.101) |
| Platelet count (× 109/L) | < 0.001 | 0.053 | 0.996 (0.992, 1.000) |
| ALT (IU/L) | < 0.001 | 0.077 | 0.997 (0.994, 1.000) |
| Gamma-GT (IU/L) | 0.019 | 0.03 | 1.002 (1.000, 1.004) |
| Serum creatinine (mg/dL) | 0.388 | 0.236 | 0.667 (0.342, 1.303) |
| 4—7 Log10 HBV DNA (IU/mL)† | < 0.001 | 0.030 | 1.631 (1.048, 2.537) |
†The proportional hazard assumption is not met. The hazard ratio is provided for descriptive purposes.
Abbreviation: HR, hazard ratio; CI, confidence interval; BSV, besifovir dipivoxil maleate; ETV, entecavir; BSV, besifovir dipivoxil maleate; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ALT, alanine aminotransferase; Gamma-GT; gamma-glutamyl transferase.